Median Overall Survival was 8 Years Longer for Women who were Treated with Therapies Consistent with Caris Molecular Intelligence™ Tumor Profiling Prediction and was 2 ½ years Longer after Recurrence
Irving, TX, June 5, 2014 –– Caris Life Sciences® and investigators from Inova Fairfax Hospital presented the first clinical outcomes data presentation from the Caris Registry™ at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., this weekend. This data, focusing on patients with ovarian cancer, demonstrated significant improvement in survival in women with ovarian cancer.
“We have long hypothesized that personalizing ovarian cancer therapy selection through tumor profiling would benefit patients, and this study is a promising step forward in validating that premise for these patients,” said William McGuire, M.D., Inova Fairfax Hospital.
Additionally, this data demonstrates the importance of avoiding inappropriate therapy. “We have found that the underlying biology is also a powerful predictor of therapies that should be avoided for ovarian cancer patients. Patients who receive a cytotoxic agent when their tumor is not likely to respond, experience a significant negative impact on survival,” said David Spetzler, Ph.D., Vice President, Research & Development, Caris Life Sciences. “Thus a patient’s outcome is strongly influenced by the ability to select appropriate therapies and avoid inappropriate therapies enhanced with the knowledge of the underlying tumor biology provided by Caris Molecular Intelligence™ service.”
Based on a 450 patient cohort, this data reported that treatments consistent with the predictions of molecular profiling significantly improved overall survival in patients with ovarian, primary peritoneal and fallopian tube carcinomas. Patients were stratified based on the chemotherapeutic agents administered during the course of their disease. Of the 450 patients, there were 278 that could be grouped into two cohorts, those whose treatments were predicted to be of benefit (170) and those who received at least one treatment predicted to be of lack of benefit (178). There were no significant differences in the baseline characteristics of these two cohorts.
Select highlights from this clinical study include:
- Patients in the Benefit cohort experienced significantly longer post-profiling survival, as evidenced by a 46 percent reduction in the risk of death, compared to the Lack of Benefit cohort (Hazard Ratio = 0.54, 95 percent CI 0.37-0.80; p=0.0018).
- Median overall survival observed for patients included in the Benefit cohort (158.0 months) compared to patients included in the Lack of Benefit cohort (63.4 months).
- Patients in the Benefit cohort also trended toward significantly longer overall survival, as evidenced by a 31 percent reduction in the risk of death, compared to the Lack of Benefit cohort (Hazard Ratio = 0.69, 95 percent CI 0.47-1.02; p=0.065).
“Oncologists dealing with particularly complex cancers should realize the value that molecular profiling with Caris Molecular Intelligence can play in helping their patients battle this disease as demonstrated by these data,” said Caris Life Sciences Chief Medical Officer, Sandeep K. Reddy, M.D.
Caris Life Sciences presented an extraordinary amount of data at ASCO through oral presentation, poster highlights, and posters.
About Caris Molecular Intelligence™
Caris Molecular Intelligence™, the industry’s leading cancer molecular profiling service, helps oncologists treat cancer smarter by delivering the most potential treatment options for patients. This service has been used by more than 6,000 oncologists to develop individualized and actionable treatment plans for more than 60,000 cancer patients in 59 countries across the globe. Caris Molecular Intelligence integrates the latest relevant panomics data – the combination of genes, proteins, molecular pathways, and unique patient characteristics – from clinical studies in cancer and cancer biology to identify the most clinically actionable drug associations approved by the U.S. Food & Drug Administration or in active clinical trials in the United States. Beyond standard DNA analysis, Caris Molecular Intelligence assesses all relevant biological components, such as RNA, protein expression and gene amplification levels, to provide oncologists with the most treatment options for their patients. Currently, Caris can identify therapeutic guidance for up to 51 FDA approved drug associations, far exceeding the 19 that can be identified using next-generation sequencing alone. This therapeutic guidance is electronically delivered to the ordering physician in an easy-to-read report that enables development of tailored treatment plans. The Caris Registry™ is a database of clinicopathologic and outcome variables from consenting patients whose tumors underwent multi-technology profiling by Caris Molecular Intelligence™.
About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of precision medicine. Caris Molecular Intelligence™, the industry’s first and largest tumor profiling service, provides an oncologist with the most potentially clinically actionable treatment options available to personalize care today. Using a variety of advanced and clinically-relevant technologies that assess all relevant biological components of a patient’s cancer, Caris Molecular Intelligence correlates molecular data generated from a tumor with biomarker/drug associations derived from clinical cancer literature. The company is also developing a series of blood tests based on its proprietary Carisome® TOP™ platform, a revolutionary blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets.
# # #
Media Inquiries:
David Patti
JFK Communications
dpatti@jfkhealth.com